Another limitation is the lack of further vascular disease measurements e.g. inflammatory markers such as ICAM-1, VCAM-1, IL-8, MCP-1, etc. Furthermore exploring liver disease formation i.e. NASH or NAFLD would have been interesting in our animal model due to the existing association between the components of MetS (i.e. visceral obesity, insulin resistance and dyslipidemia) and NALD/NASH. The gene discussed is CCL2; the disease is metabolic dysfunction-associated steatohepatitis.